Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alectinib · 1 trial · 4 indications
Response according to RECIST
| Arm | Type | Description |
|---|---|---|
| Alectinib | EXPERIMENTAL | Alectinib for patients with a molecular tumor profile that can potentially be targeted by Alectinib. |
| Atezolizumab | EXPERIMENTAL | Atezolizumab for patients with a molecular tumor profile that can potentially be targeted by Atezolizumab. |
| Avelumab | EXPERIMENTAL | Avelumab for patients with a molecular tumor profile that can potentially be targeted by Avelumab. |
| Axitinib | EXPERIMENTAL | Axitinib for patients with a molecular tumor profile that can potentially be targeted by Axitinib. |
| Erlotinib | EXPERIMENTAL | Erlotinib for patients with a molecular tumor profile that can potentially be targeted by Erlotinib. |
| Vemurafenib plus Cobimetinib (combination) | EXPERIMENTAL | Vemurafenib plus Cobimetinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Vemurafenib plus Cobimetinib. |
| Trastuzumab plus Pertuzumab (combination) | EXPERIMENTAL | Trastuzumab plus Pertuzumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab plus Pertuzumab. |
| Trastuzumab emtansin | EXPERIMENTAL | Trastuzumab emtansin for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab emtansin. |
| Vismodegib | EXPERIMENTAL | Vismodegib for patients with a molecular tumor profile that can potentially be targeted by Vismodegib. |
| Niraparib | EXPERIMENTAL | Niraparib for patients with a molecular tumor profile that can potentially be targeted by Niraparib. |
| Name | Type | Description |
|---|---|---|
| Alectinib | DRUG | Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile. |
| Atezolizumab | DRUG | Atezolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab might be expected based on their molecular tumor profile. |
| Avelumab | DRUG | Avelumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Avelumab might be expected based on their molecular tumor profile. |
| Axitinib | DRUG | Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile. |
| Erlotinib | DRUG | Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Erlotinib might be expected based on their molecular tumor profile. |
| Vemurafenib plus Cobimetinib (combination) | DRUG | Vemurafenib plus Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib plus Cobimetinib might be expected based on their molecular tumor profile. |
| Trastuzumab plus Pertuzumab (combination) | DRUG | Trastuzumab plus Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab plus Pertuzumab might be expected based on their molecular tumor profile. |
| Trastuzumab emtansine | DRUG | Trastuzumab emtansine treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab emtansine might be expected based on their molecular tumor profile. |
| Vismodegib | DRUG | Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vismodegib might be expected based on their molecular tumor profile. |
| Niraparib | DRUG | Niraparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Niraparib might be expected based on their molecular tumor profile. |
Inclusion Criteria: 1. Patient (age≥ 18 years) with a histologically-proven locally advanced or metastatic malignant disease who is no longer benefitting from standard anti-cancer treatment or for whom, in the opinion of the investigator, no such treatment is available or indicated. 2. ECOG perform...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
Alectinib is an investigational small molecule being studied for the treatment of cancer, including tumors and neoplasms. It is currently in Phase 2 clinical development as part of a targeted cancer treatment approach based on genomic profiling. The drug is being evaluated in a controlled clinical trial in Denmark.
Alectinib targets ALK, EML4, and RET. It is an inhibitor of these molecular targets, which are relevant in certain cancers. By inhibiting these targets, Alectinib is being studied for its potential role in treating cancer, particularly in patients selected based on biomarker profiles.
Alectinib is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is currently in Phase 2 clinical trials for cancer, with an active study recruiting participants in Denmark.
Alectinib is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 2 trial is actively recruiting patients with cancer, tumors, or neoplasms, and is designed as a controlled study.
Alectinib is being studied in the clinical trial NCT04341181, titled 'ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling.' This Phase 2 trial is recruiting 300 participants aged 18 years and older with cancer, tumors, or neoplasms in Denmark. The study is biomarker-selected and controlled.
Alectinib is also known by the ChEMBL identifier CHEMBL1738797. This identifier is used in chemical and biological databases to reference the compound. No other alternative names for Alectinib have been disclosed in the available information.